HOME > LATEST
LATEST
-
BUSINESS Enhertu Filed for HER2 Positive Solid Tumors in Japan
April 25, 2025
-
BUSINESS Sanofi Looks to Join Top 3 in Japan Pharma Market by 2030
April 25, 2025
-
BUSINESS Meiji’s Rezurock Grabs Approval in Taiwan
April 25, 2025
-
REGULATORY “Time to Revise” Fee Premiums for Generic Use: Chuikyo Payer Rep
April 25, 2025
-
REGULATORY LDP Group Calls for Keeping Health Coverage for Pain Relief Patches
April 25, 2025
-
BUSINESS Novo Unveils 4 Billion Yen Investment in Japan Factory
April 24, 2025
-
ORGANIZATION US Tariffs Would Hinder Access to Innovative Drugs: JPMA President
April 24, 2025
-
REGULATORY MHLW to Present Estimate on Coverage Removal of OTC-Like Meds at 3-Party Talks
April 24, 2025
-
REGULATORY MOF’s Spring Debate Puts Special Focus on CEA, More Aggressive Re-Pricing Eyed
April 24, 2025
-
BUSINESS Japan Approves Spikevax’s Prefilled Syringe Version
April 24, 2025
-
REGULATORY Epkinly to Face Price Cuts under CEA Scheme
April 24, 2025
-
BUSINESS Takeda’s Japan Earnings Bottomed Out, Now on Pace to Growth from FY2025: Head
April 23, 2025
-
BUSINESS BeiGene Sees Better-than-Expected Uptake for Brukinsa after March Launch
April 23, 2025
-
BUSINESS CSL to Join Forces with Specialists to Raise Awareness of HAE: Japan President
April 23, 2025
-
BUSINESS Fujifilm CDMO Strikes US$3 Billion Manufacturing Deal with Regeneron
April 23, 2025
-
BUSINESS Vital-Net Bags Japan Rights to Shield’s Iron Deficiency Med
April 23, 2025
-
REGULATORY Biosimilars Should Be Mentioned in Honebuto: LDP Pharma Affairs Panel Chair
April 23, 2025
-
REGULATORY New Usages of Anaemetro, Raiatt Now Eligible for Health Coverage
April 23, 2025
-
REGULATORY Bill to Amend PMD Act Now in Upper House Deliberations
April 23, 2025
-
ORGANIZATION JPMA to Discuss Ways to Promote DX in Commercial Production in FY2025
April 23, 2025
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…